Each month I’m surprised by the large number of studies done with ketamine, especially when compared to the small number of psilocybin and MDMA studies. This month also features some of those, one comparing ketamine unfavorably to ECT. Psychedelics for anxiety disorder and psilocybin specifically for OCD are also reviewed. A small study with MDMA in Brazil is reported, and exploratory research with 5-MeO-DMT and ibogaine see extraordinary results for trauma with veterans.